The U.S. Food and Drug Administration’s (FDA) Committee on Food and Drug Administration under the U.S. Department of Health and Human Services has licensed Pfizer’s COVID-19 vaccine for use in emergencies.
“The decision means millions of people will begin receiving the vaccine in the next few days,” the newspaper wrote. Data on the licensing were provided by three anonymous sources.
It was also reported that medics and the elderly should be the first to receive the drug, and delivery of the vaccine will begin within 24 hours after it is licensed.
On Friday, Dec. 11, the FDA recommended that management approve the Pfizer/BioNTech coronavirus vaccine. FDA experts called for approval of the vaccine’s fast-track emergency registration. In the final vote, committee staff responded in the affirmative to the question of whether the benefits of the vaccine outweigh the associated risks. Management will review the committee’s recommendations and decide on the application “as quickly as possible.”
So far, there are several vaccines against COVID-19 in the world. For example, two vaccines have been registered in Russia: Sputnik V and EpiVacCorona. On December 5, vaccination against coronavirus with Sputnik V started in Moscow. A COVID-19 vaccine produced by Pfizer/BioNTech has been registered in the United States, with another Moderna vaccine on the way.